# Factors Influencing Liver Abnormalities in Psoriatic Arthritis Patients: A Comprehensive Study

## TL;DR

This study finds that psoriatic arthritis patients with longer disease duration, diabetes, or fatty liver disease are more likely to develop liver abnormalities.

## Contribution

The study identifies specific risk factors for liver abnormalities in psoriatic arthritis patients through a longitudinal cohort analysis.

## Key findings

- 99 out of 247 psoriatic arthritis patients developed liver enzyme abnormalities.
- Disease duration, diabetes mellitus, and non-alcoholic fatty liver disease were significantly associated with liver abnormalities.
- No link was found between liver abnormalities and use of disease-modifying antirheumatic drugs or biologics.

## Abstract

The aim of this study was to establish the incidence of liver abnormalities in psoriatic arthritis patients and identify the factors that contributed to this condition.

This is a longitudinal cohort study. Psoriatic arthritis (PsA) patients with liver enzymes abnormalities were identified. Our control group consisted of PsA patient from the same cohort who had no history of liver abnormalities. Factors associated with liver abnormalities were identified using univariate and multivariate analysis.

A total of 247 of PsA patients were included and out of those, 99 developed liver enzymes abnormalities. The mean age of the patients was 56 years old (±13.5) with 56.1% female and 39.4% Indian descendants. The univariate logistic regression demonstrated that disease duration of PsA (OR=1.06, 95% CI=1.01 - 1.10, p=0.012), diabetes mellitus (OR=2.16, 95% CI=1.26 - 3.70, 0.005) and non-alcoholic fatty liver disease (NAFLD) (OR=3.90, 95% CI = 1.44 - 10.53, p=0.007) were associated with abnormal liver function in PsA patients. No association was found with both conventional synthetic disease-modifying antirheumatic drugs or biologics.

Liver enzymes abnormalities in PsA patients were linked to disease duration, diabetes mellitus and NAFLD. For these high-risk populations, vigilant monitoring of liver function tests is vital for early detection and intervention.